-
Hill-Rom Reports EPS of $0.52 vs. $0.50 Estimate; Revenues $402.1M vs. $377.5M Estimate (HRC)
Wednesday, April 27, 2011 - 5:04pm | 21Hill-Rom (NYSE: HRC) Reports EPS of $0.52 vs. $0.50 Estimate; Revenues $402.1M vs. $377.5M Estimate
-
VP of St. Jude Sells 133,750 Shares at $51.80/Share for $7 Million (STJ)
Wednesday, April 27, 2011 - 4:39pm | 23VP of St. Jude, Pamela Krop, Sells 133,750 Shares at $51.80/Share for $7 Million Proceeds (NYSE: STJ)
-
Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)
Wednesday, April 27, 2011 - 3:28pm | 1526Point Roberts, WA - April 27, 2011 - Investorideas.com, a leader in sector stock research including biotech/pharma stocks, reports on new trends in the healthcare sector where the industry is reporting that medical technology is on the rise, and the development of new drugs may be slowing down. The...
-
Standpoint Research Downgrades Zimmer Holdings to Hold (ZMH)
Wednesday, April 27, 2011 - 2:18pm | 19Standpoint Research downgrades Zimmer Holdings (NYSE: ZMH) from Buy to Hold.
-
Citi Maintains Buy on Spectranetics (SPNC)
Wednesday, April 27, 2011 - 9:19am | 164Citi is out with its report today on Spectranetics (NASDAQ: SPNC), maintaining Buy. In a note to clients, Citi writes, "Our investment thesis for Spectranetics, which is rated Buy/Speculative (1S), is as follows: (1) With 10 million patients with PAD in the US, but only 2 million diagnosed, the...
-
NxStage® Names Michael Miller, Jr. President, International (NXTM)
Wednesday, April 27, 2011 - 8:07am | 147NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Michael Miller, Jr., former Senior Vice President and General Manager of the Cardiac Care Business at Philips Healthcare, has joined the NxStage senior management team in the newly-...
-
Update: Citi Raising Price Target On Hospira (HSP)
Wednesday, April 27, 2011 - 7:34am | 114Citi Investment Research is raising its price target on shares of Hospira (NYSE: HSP) to $54 from $52, but is keeping its Sell rating after the company reported earnings. In a note to investors, Citi writes, "HSP reported solid 1Q upside and announced a $1B share repurchase program, but failed...
-
Morgan Stanley Overweight On Resmed Inc. (RMD)
Wednesday, April 27, 2011 - 7:28am | 127Morgan Stanley has an Overweight rating and a $34.98 price target on shares of Resmed Inc. (NYSE: RMD), as it previews earnings. In a note to investors, Morgan Stanley writes, "RMD's lack of a bi-level device on the S9 platform leads to poor 2Q11 performance at only 1.9% growth in the US....
-
Active Screen - CANSLIM: Top 8 for April 27th
Wednesday, April 27, 2011 - 7:10am | 1355There were a couple of changes to the top-8 constituents this week. Dropped were Intuitive Surgical (ISRG) and Free McMoran (FCX), returning were Netflix (NFLX) and F5 Networks (FFIV). The complete list is as follows: Apple (AAPL), Vale S.A. (VALE), Barrick Gold (ABX), Baidu (BIDU), Research in...
-
Spectranetics Achieves Record Revenue of $30.4 Million in First Quarter
Wednesday, April 27, 2011 - 6:57am | 55Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the quarter ended March 31, 2011. The quarter's highlights include: Record revenue of $30.4 million achieved, representing 5% growth over prior year first quarter Lead Management revenue increased 14% compared with...
-
JP Morgan Raises PT On Hospira To $66
Wednesday, April 27, 2011 - 6:39am | 26JP Morgan has raised the price target on Hospira (NYSE: HSP) from $64 to $66 and maintains its Overweight rating.
-
Jefferies Raises PT On Becton, Dickinson & Company To $98
Wednesday, April 27, 2011 - 6:32am | 29Jefferies & Company has raised the price target on Becton, Dickinson and Company (NYSE: BDX) from $96 to $98 and maintains its Buy rating.
-
JP Morgan Raises PT On Kinetic Concepts To $56
Wednesday, April 27, 2011 - 6:29am | 27JP Morgan has raised the price target on Kinetic Concepts (NYSE: KCI) from $46 to $56 and maintains its Neutral rating.
-
Trading on Johnson & Johnson's $21.3 Billion Purchase of Synthes (JNJ, MDT, BSX, TMO, IHI)
Wednesday, April 27, 2011 - 6:14am | 411New Brunswick, New Jersey-based Johnson & Johnson (NYSE: JNJ) and Synthes, Inc. announced early on Wednesday morning that the two companies had reached an agreement for Johnson & Johnson to buy the Swiss company for 159 Swiss francs per share, or a total of US$21.3 billion at current...
-
Citigroup Downgrades Hospira To Sell, PT to $54
Wednesday, April 27, 2011 - 5:56am | 26Citigroup has downgraded Hospira (NYSE: HSP) from Hold to Sell and has raised the price target from $52 to $54.